Identifying biomarkers in lung transplant recipients
Biomolecular Phenotyping of Lung Transplant Recipients: a Prospective Observational Study
This study is trying to find specific blood markers in lung transplant patients to better understand and treat a common complication called primary graft dysfunction.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Policlinico Hospital Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06125535 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on primary graft dysfunction (PGD), a common complication following lung transplants that affects about 30% of patients within 72 hours. The researchers aim to classify lung transplant patients based on their blood markers related to inflammation and other factors, using a precision medicine approach to tailor treatments to different patient subgroups. By understanding the varying levels of PGD severity and its systemic effects, the study seeks to improve treatment strategies for affected patients. This innovative approach has shown promise in other critical conditions, such as acute respiratory distress syndrome.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 who have undergone double lung transplants.
Not a fit: Patients who have had a single lung transplant or are undergoing re-transplantation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatments for lung transplant recipients suffering from primary graft dysfunction.
How similar studies have performed: While similar approaches have been successful in treating conditions like acute respiratory distress syndrome, this specific application in lung transplant patients is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * undergone double LUTX * age \> 18 years old Exclusion Criteria: * single LUTX * re-transplantation * bridge-to-LUTX by extracorporeal membrane oxygenation
Where this trial is running
Milan
- Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Vittorio Scaravilli, MD — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Study coordinator: Vittorio Scaravilli, MD
- Email: vittorio.scaravilli@unimi.com
- Phone: 0255033275
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.